BTK抑制剂-话题@MedSci

#BTK抑制剂#

60篇内容 | 3430人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1297398, encodeId=5ccd129e3985f, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, objectTitle=Blood：3期试验：两组BTK抑制剂治疗华氏巨球蛋白血症！, objectType=article, longId=198977, objectId=96891989e774, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=96891989e774, replyNumber=0, likeNumber=99, createdTime=2020-08-09, rootId=0, userName=zhixianchen, userId=1e72268, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=96891989e774, moduleTitle=Blood：3期试验：两组BTK抑制剂治疗华氏巨球蛋白血症！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=96891989e774)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1297397, encodeId=8e80129e39728, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, objectTitle=Blood：BTK抑制剂泽布替尼治疗华氏巨球蛋白血症的疗效, objectType=article, longId=198725, objectId=5d63198e2565, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d63198e2565, replyNumber=0, likeNumber=118, createdTime=2020-08-06, rootId=0, userName=zhixianchen, userId=1e72268, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d63198e2565, moduleTitle=Blood：BTK抑制剂泽布替尼治疗华氏巨球蛋白血症的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5d63198e2565)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1297396, encodeId=36d4129e39666, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, objectTitle=Clini Cancer Research：新型BTK抑制剂Zanubrutinib治疗复发性/难治性MCL, objectType=article, longId=197074, objectId=2ffd19e07469, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2ffd19e07469, replyNumber=0, likeNumber=93, createdTime=2020-07-06, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2ffd19e07469, moduleTitle=Clini Cancer Research：新型BTK抑制剂Zanubrutinib治疗复发性/难治性MCL, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2ffd19e07469)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1297395, encodeId=e38c129e39568, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, objectTitle=Bcl-2联合BTK抑制剂治疗慢性淋巴细胞淋巴瘤, objectType=article, longId=196296, objectId=7b82196296b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b82196296b4, replyNumber=0, likeNumber=98, createdTime=2020-06-24, rootId=0, userName=zhixianchen, userId=1e72268, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b82196296b4, moduleTitle=Bcl-2联合BTK抑制剂治疗慢性淋巴细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7b82196296b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1297394, encodeId=3f63129e394c1, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, objectTitle=百济神州的BTK抑制剂Brukinsa，在欧洲接受审查用于治疗华氏巨球蛋白血症, objectType=article, longId=196197, objectId=35d019619e84, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=35d019619e84, replyNumber=0, likeNumber=114, createdTime=2020-06-22, rootId=0, userName=zhixianchen, userId=1e72268, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=35d019619e84, moduleTitle=百济神州的BTK抑制剂Brukinsa，在欧洲接受审查用于治疗华氏巨球蛋白血症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=35d019619e84)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1297393, encodeId=80a9129e39301, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, objectTitle=BTK抑制剂Calquence：显著缓解新冠病毒COVID-19感染患者体内的细胞因子风暴, objectType=article, longId=195498, objectId=094219549826, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=094219549826, replyNumber=0, likeNumber=84, createdTime=2020-06-10, rootId=0, userName=zhixianchen, userId=1e72268, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=094219549826, moduleTitle=BTK抑制剂Calquence：显著缓解新冠病毒COVID-19感染患者体内的细胞因子风暴, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=094219549826)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1297392, encodeId=ba2a129e392eb, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, objectTitle=EAN 2020：BTK抑制剂Evobrutinib治疗复发性多发性硬化症的有效性和安全性良好, objectType=article, longId=194711, objectId=2e1a194e1115, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e1a194e1115, replyNumber=0, likeNumber=91, createdTime=2020-05-27, rootId=0, userName=zhixianchen, userId=1e72268, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e1a194e1115, moduleTitle=EAN 2020：BTK抑制剂Evobrutinib治疗复发性多发性硬化症的有效性和安全性良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e1a194e1115)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1297391, encodeId=372d129e39138, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, objectTitle=实验性BTK抑制剂SAR442168可显著降低多发性硬化症的疾病活动, objectType=article, longId=192862, objectId=cb3a1928621f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb3a1928621f, replyNumber=0, likeNumber=88, createdTime=2020-04-25, rootId=0, userName=zhixianchen, userId=1e72268, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb3a1928621f, moduleTitle=实验性BTK抑制剂SAR442168可显著降低多发性硬化症的疾病活动, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb3a1928621f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1297390, encodeId=4a9b129e39055, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, objectTitle=BTK抑制剂Calquence治疗COVID-19感染相关的细胞因子风暴, objectType=article, longId=192295, objectId=7d35192295a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d35192295a3, replyNumber=0, likeNumber=72, createdTime=2020-04-16, rootId=0, userName=zhixianchen, userId=1e72268, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7d35192295a3, moduleTitle=BTK抑制剂Calquence治疗COVID-19感染相关的细胞因子风暴, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7d35192295a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1297389, encodeId=d9b1129e3891e, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, objectTitle=Blood：BTK抑制剂疗法可有效治疗venetoclax耐药性CLL, objectType=article, longId=191569, objectId=228219156976, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=228219156976, replyNumber=0, likeNumber=107, createdTime=2020-04-08, rootId=0, userName=zhixianchen, userId=1e72268, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=228219156976, moduleTitle=Blood：BTK抑制剂疗法可有效治疗venetoclax耐药性CLL, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=228219156976)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1297388, encodeId=e709129e3888f, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, objectTitle=Blood：选择性BTK抑制剂acalabrutinib治疗慢淋白血病的事宜剂量及疗效, objectType=article, longId=190747, objectId=c318190e4795, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c318190e4795, replyNumber=0, likeNumber=93, createdTime=2020-03-26, rootId=0, userName=zhixianchen, userId=1e72268, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c318190e4795, moduleTitle=Blood：选择性BTK抑制剂acalabrutinib治疗慢淋白血病的事宜剂量及疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c318190e4795)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1297387, encodeId=4689129e387a2, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, objectTitle=复发性多发性硬化症（MS）的治疗再迎进展：BTK抑制剂SAR442168达到中期研究的主要终点, objectType=article, longId=187657, objectId=c23618e6572f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c23618e6572f, replyNumber=0, likeNumber=59, createdTime=2020-02-09, rootId=0, userName=zhixianchen, userId=1e72268, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c23618e6572f, moduleTitle=复发性多发性硬化症（MS）的治疗再迎进展：BTK抑制剂SAR442168达到中期研究的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c23618e6572f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1297386, encodeId=bae9129e386ca, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, objectTitle=Blood：BTK抑制剂acalabrutinib治疗复发性/难治性CLL/SLL, objectType=article, longId=185326, objectId=ed2f185326f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed2f185326f5, replyNumber=0, likeNumber=114, createdTime=2019-12-29, rootId=0, userName=zhixianchen, userId=1e72268, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed2f185326f5, moduleTitle=Blood：BTK抑制剂acalabrutinib治疗复发性/难治性CLL/SLL, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed2f185326f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1297385, encodeId=a588129e38583, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, objectTitle=头对头临床试验：百济神州的BTK抑制剂Brukinsa未能击败强生/艾伯维的Imbruvica, objectType=article, longId=184955, objectId=41c3184955ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=41c3184955ce, replyNumber=0, likeNumber=82, createdTime=2019-12-21, rootId=0, userName=zhixianchen, userId=1e72268, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=41c3184955ce, moduleTitle=头对头临床试验：百济神州的BTK抑制剂Brukinsa未能击败强生/艾伯维的Imbruvica, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=41c3184955ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1297384, encodeId=7bea129e3844b, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, objectTitle=2019 ASH：阿斯利康的BTK抑制剂Calquence提高了慢性淋巴细胞白血病患者的无进展生存期, objectType=article, longId=184850, objectId=079b184850dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=079b184850dc, replyNumber=0, likeNumber=76, createdTime=2019-12-18, rootId=0, userName=zhixianchen, userId=1e72268, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=079b184850dc, moduleTitle=2019 ASH：阿斯利康的BTK抑制剂Calquence提高了慢性淋巴细胞白血病患者的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=079b184850dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1297383, encodeId=ab7d129e3838a, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, objectTitle=BTK抑制剂ONO-4059寻求在日本的生产和销售许可，用于治疗华氏巨球蛋白血症和淋巴浆细胞性淋巴瘤, objectType=article, longId=183717, objectId=9ef0183e173f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ef0183e173f, replyNumber=0, likeNumber=65, createdTime=2019-11-30, rootId=0, userName=zhixianchen, userId=1e72268, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ef0183e173f, moduleTitle=BTK抑制剂ONO-4059寻求在日本的生产和销售许可，用于治疗华氏巨球蛋白血症和淋巴浆细胞性淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9ef0183e173f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1297382, encodeId=2124129e38244, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, objectTitle=FDA批准阿斯利康的BTK抑制剂Calquence，用于治疗慢性淋巴细胞白血病和小淋巴细胞淋巴瘤, objectType=article, longId=183460, objectId=fde3183460df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fde3183460df, replyNumber=0, likeNumber=68, createdTime=2019-11-24, rootId=0, userName=zhixianchen, userId=1e72268, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fde3183460df, moduleTitle=FDA批准阿斯利康的BTK抑制剂Calquence，用于治疗慢性淋巴细胞白血病和小淋巴细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fde3183460df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1297381, encodeId=cf85129e381a8, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, objectTitle=百济神州的BTK抑制剂Brukinsa，成为国内获得FDA批准的抗癌药物, objectType=article, longId=183115, objectId=e7431831158c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e7431831158c, replyNumber=0, likeNumber=76, createdTime=2019-11-19, rootId=0, userName=zhixianchen, userId=1e72268, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e7431831158c, moduleTitle=百济神州的BTK抑制剂Brukinsa，成为国内获得FDA批准的抗癌药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e7431831158c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1297380, encodeId=ea7f129e380b8, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, objectTitle=【2019 CSCO】国内白血病·淋巴瘤专场：聚焦淋巴瘤治疗前沿，BTK抑制剂在B细胞淋巴瘤中应用前景广阔, objectType=article, longId=180451, objectId=021e180451ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=021e180451ba, replyNumber=0, likeNumber=73, createdTime=2019-10-05, rootId=0, userName=zhixianchen, userId=1e72268, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=021e180451ba, moduleTitle=【2019 CSCO】国内白血病·淋巴瘤专场：聚焦淋巴瘤治疗前沿，BTK抑制剂在B细胞淋巴瘤中应用前景广阔, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=021e180451ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1297379, encodeId=5d91129e379eb, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, objectTitle=新型BTK抑制剂泽布替尼在非霍奇金淋巴瘤中的应用进展, objectType=article, longId=178673, objectId=a1651e867369, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a1651e867369, replyNumber=0, likeNumber=72, createdTime=2019-09-04, rootId=0, userName=zhixianchen, userId=1e72268, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a1651e867369, moduleTitle=新型BTK抑制剂泽布替尼在非霍奇金淋巴瘤中的应用进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a1651e867369)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

BTK抑制剂

2020-05-29

zhixianchen (审核中...)

前往app查看评论内容

#BTK抑制剂#

Blood：3期试验：两组BTK抑制剂治疗华氏巨球蛋白血症！

2020-08-09

zhixianchen (审核中...)

前往app查看评论内容

#BTK抑制剂#

Blood：BTK抑制剂泽布替尼治疗华氏巨球蛋白血症的疗效

2020-08-06

智者为医08 (审核中...)

前往app查看评论内容

#BTK抑制剂#

Clini Cancer Research：新型BTK抑制剂Zanubrutinib治疗复发性/难治性MCL

2020-07-06

zhixianchen (审核中...)

前往app查看评论内容

#BTK抑制剂#

Bcl-2联合BTK抑制剂治疗慢性淋巴细胞淋巴瘤

2020-06-24

zhixianchen (审核中...)

前往app查看评论内容

#BTK抑制剂#

百济神州的BTK抑制剂Brukinsa，在欧洲接受审查用于治疗华氏巨球蛋白血症

2020-06-22

zhixianchen (审核中...)

前往app查看评论内容

#BTK抑制剂#

BTK抑制剂Calquence：显著缓解新冠病毒COVID-19感染患者体内的细胞因子风暴

2020-06-10

zhixianchen (审核中...)

前往app查看评论内容

#BTK抑制剂#

EAN 2020：BTK抑制剂Evobrutinib治疗复发性多发性硬化症的有效性和安全性良好

2020-05-27

zhixianchen (审核中...)

前往app查看评论内容

#BTK抑制剂#

实验性BTK抑制剂SAR442168可显著降低多发性硬化症的疾病活动

2020-04-25

zhixianchen (审核中...)

前往app查看评论内容

#BTK抑制剂#

BTK抑制剂Calquence治疗COVID-19感染相关的细胞因子风暴

2020-04-16

zhixianchen (审核中...)

前往app查看评论内容

#BTK抑制剂#

Blood：BTK抑制剂疗法可有效治疗venetoclax耐药性CLL

2020-04-08

zhixianchen (审核中...)

前往app查看评论内容

#BTK抑制剂#

Blood：选择性BTK抑制剂acalabrutinib治疗慢淋白血病的事宜剂量及疗效

2020-03-26

zhixianchen (审核中...)

前往app查看评论内容

#BTK抑制剂#

复发性多发性硬化症（MS）的治疗再迎进展：BTK抑制剂SAR442168达到中期研究的主要终点

2020-02-09

zhixianchen (审核中...)

前往app查看评论内容

#BTK抑制剂#

Blood：BTK抑制剂acalabrutinib治疗复发性/难治性CLL/SLL

2019-12-29

zhixianchen (审核中...)

前往app查看评论内容

#BTK抑制剂#

头对头临床试验：百济神州的BTK抑制剂Brukinsa未能击败强生/艾伯维的Imbruvica

2019-12-21

zhixianchen (审核中...)

前往app查看评论内容

#BTK抑制剂#

2019 ASH：阿斯利康的BTK抑制剂Calquence提高了慢性淋巴细胞白血病患者的无进展生存期

2019-12-18

zhixianchen (审核中...)

前往app查看评论内容

#BTK抑制剂#

BTK抑制剂ONO-4059寻求在日本的生产和销售许可，用于治疗华氏巨球蛋白血症和淋巴浆细胞性淋巴瘤

2019-11-30

zhixianchen (审核中...)

前往app查看评论内容

#BTK抑制剂#

FDA批准阿斯利康的BTK抑制剂Calquence，用于治疗慢性淋巴细胞白血病和小淋巴细胞淋巴瘤

2019-11-24

zhixianchen (审核中...)

前往app查看评论内容

#BTK抑制剂#

百济神州的BTK抑制剂Brukinsa，成为国内获得FDA批准的抗癌药物

2019-11-19

zhixianchen (审核中...)

前往app查看评论内容

#BTK抑制剂#

【2019 CSCO】国内白血病·淋巴瘤专场：聚焦淋巴瘤治疗前沿，BTK抑制剂在B细胞淋巴瘤中应用前景广阔

2019-10-05

zhixianchen (审核中...)

前往app查看评论内容

#BTK抑制剂#

新型BTK抑制剂泽布替尼在非霍奇金淋巴瘤中的应用进展

2019-09-04

科室
- - 订阅+
  - 更多科室
工具
服务